Abbreviations
医学略語
本文で使っているアルファベット略語と全文の対応。910 語、延べ 95,686 回。 本文では各ページの初出でのみ「略語(全文)」と併記し、 2回目以降は略語のままにしています。日本語表示・英語表示のどちらでも入れ替えません。 アルファベット順。
910 / 910 件を表示中
| 略語 | 全文 | 出現 |
|---|---|---|
| 11β-HSD2 | 11beta-hydroxysteroid dehydrogenase type 2 | 19 |
| 17-OHCS | 17-hydroxycorticosteroids | 2 |
| 17-OHP | 17-hydroxyprogesterone | 61 |
| 177Lu-DOTATATE | lutetium-177 DOTATATE | 4 |
| 18F-FDG PET | fluorine-18 FDG PET | 3 |
| 18F-FDOPA | fluorine-18 fluorodopa | 1 |
| 2-HG | 2-hydroxyglutarate | 11 |
| 2MWT | two-minute walk test | 19 |
| 5-FU | 5-fluorouracil | 90 |
| 5-HIAA | 5-hydroxyindoleacetic acid | 50 |
| 68Ga-DOTATATE PET/CT | gallium-68 DOTATATE PET/CT | 8 |
| 6MWT | 6-minute walk test | 18 |
| ABCA1 | ATP-binding cassette transporter A1 | 35 |
| ABI | ankle-brachial index | 79 |
| ABPA | allergic bronchopulmonary aspergillosis | 73 |
| ABUS | automated breast ultrasound | 1 |
| ACE | angiotensin-converting enzyme | 972 |
| ACE2 | angiotensin-converting enzyme 2 | 40 |
| ACG | American College of Gastroenterology | 324 |
| AChE | acetylcholinesterase | 157 |
| ACIP | Advisory Committee on Immunization Practices | 14 |
| ACPA | anti-citrullinated protein antibody | 35 |
| ACR TI-RADS | American College of Radiology Thyroid Imaging Reporting and Data System | 10 |
| ACTH | adrenocorticotropic hormone | 724 |
| ADC | apparent diffusion coefficient | 112 |
| ADCC | antibody-dependent cellular cytotoxicity | 61 |
| ADHD | attention-deficit/hyperactivity disorder | 152 |
| ADL | activities of daily living | 63 |
| AF | atrial fibrillation | 707 |
| AFP | alpha-fetoprotein | 286 |
| AGA | androgenetic alopecia | 50 |
| AGEs | advanced glycation end products | 19 |
| AhR | aryl hydrocarbon receptor | 39 |
| AICA | anterior inferior cerebellar artery | 2 |
| AIDS | acquired immunodeficiency syndrome | 636 |
| AIMS | Abnormal Involuntary Movement Scale (AIMS) | 4 |
| AJCC | American Joint Committee on Cancer | 51 |
| ALARA | as low as reasonably achievable | 19 |
| ALDP | adrenoleukodystrophy protein | 7 |
| ALI | acute limb ischemia | 36 |
| ALL | acute lymphoblastic leukemia | 146 |
| ALP | alkaline phosphatase | 171 |
| ALT | alanine aminotransferase | 350 |
| AMH | anti-Müllerian hormone | 304 |
| AML | acute myeloid leukemia | 185 |
| AMPK | AMP-activated protein kinase | 83 |
| AMPnoPRO | Amputee Mobility Predictor without prosthesis | 17 |
| AMPPRO | Amputee Mobility Predictor with prosthesis | 17 |
| AMPPRO/AMPnoPRO | AMP with prosthesis / AMP without prosthesis | 2 |
| ANA | antinuclear antibody | 240 |
| ANC | absolute neutrophil count | 357 |
| ANCA | antineutrophil cytoplasmic antibody | 812 |
| AOSC | acute obstructive suppurative cholangitis | 1 |
| aPL | antiphospholipid antibody | 18 |
| APL | acute promyelocytic leukemia | 78 |
| aPTT | activated partial thromboplastin time | 181 |
| APTT | activated partial thromboplastin time | 77 |
| ARB | angiotensin II receptor blocker | 246 |
| ARDS | acute respiratory distress syndrome | 333 |
| ARNI | angiotensin receptor-neprilysin inhibitor | 77 |
| ASCVD | atherosclerotic cardiovascular disease | 85 |
| ASPECTS | Alberta Stroke Program Early CT Score | 25 |
| AST | aspartate aminotransferase | 272 |
| ASWPD | advanced sleep-wake phase disorder | 1 |
| ATA | American Thyroid Association | 114 |
| ATL | adult T-cell leukemia-lymphoma | 91 |
| ATLS | Advanced Trauma Life Support | 47 |
| ATRA | all-trans retinoic acid | 40 |
| ATS | American Thoracic Society | 44 |
| AUA-7 | American Urological Association Symptom Index | 2 |
| AUC | area under the curve | 70 |
| AUDIT | Alcohol Use Disorders Identification Test | 20 |
| AUDIT-C | Alcohol Use Disorders Identification Test-Consumption | 3 |
| AUROC | area under the receiver operating characteristic curve | 6 |
| AUS | atypia of undetermined significance | 7 |
| AVM | arteriovenous malformation | 71 |
| AVP | arginine vasopressin | 130 |
| AVPU | alert, voice, pain, unresponsive | 27 |
| AWGS | Asian Working Group for Sarcopenia | 3 |
| BADL | basic activities of daily living | 2 |
| BAL | bronchoalveolar lavage | 131 |
| BCG | bacille Calmette-Guerin | 125 |
| BCYE | buffered charcoal yeast extract | 8 |
| bDMARD | biologic disease-modifying antirheumatic drug | 43 |
| BEP | bleomycin, etoposide, cisplatin | 40 |
| BH4 | tetrahydrobiopterin | 196 |
| BI-RADS | Breast Imaging Reporting and Data System | 11 |
| BMI | body mass index | 192 |
| BNP | B-type natriuretic peptide | 135 |
| BOOIf | female bladder outlet obstruction index | 1 |
| BOS | bronchiolitis obliterans syndrome | 3 |
| BPaLM | BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) | 31 |
| BPSD | behavioral and psychological symptoms of dementia | 15 |
| BRUE | brief resolved unexplained event | 1 |
| BSA | body surface area | 37 |
| BSEP | bile salt export pump | 10 |
| BSG | British Society of Gastroenterology | 34 |
| BSI | Bronchiectasis Severity Index | 12 |
| BSL-2 | biosafety level 2 | 5 |
| BSL-3 | biosafety level 3 | 17 |
| BSL-4 | biosafety level 4 | 11 |
| BUN | blood urea nitrogen | 94 |
| C1s | complement C1s | 28 |
| C3-C6 | typical cervical vertebrae | 1 |
| C5b-9 | membrane attack complex | 48 |
| CA-125 | cancer antigen 125 | 91 |
| CA-AKI | contrast-associated acute kidney injury | 8 |
| CA27-29 | CA 27-29 | 14 |
| CAAT | COPD Assessment Test | 15 |
| CAAT/CAT | COPD Assessment Test | 14 |
| CABG | coronary artery bypass grafting | 42 |
| CAC | coronary artery calcium | 4 |
| CAGE | CAGE questionnaire | 20 |
| CAGE-AID | CAGE Adapted to Include Drugs | 1 |
| CALR | calreticulin gene | 23 |
| cAMP | cyclic adenosine monophosphate | 299 |
| CANMAT | Canadian Network for Mood and Anxiety Treatments | 20 |
| CARPA | complement activation-related pseudoallergy | 1 |
| CASS | Composite Autonomic Severity Score | 7 |
| CBC | complete blood count | 95 |
| CBCT | cone-beam computed tomography | 7 |
| CBT | cognitive behavioral therapy | 44 |
| CCFA | cycloserine-cefoxitin-fructose agar | 2 |
| CCHF | Crimean-Congo hemorrhagic fever | 19 |
| CCK | cholecystokinin | 26 |
| CCR4 | CC chemokine receptor 4 | 26 |
| CD117 | CD117 (c-KIT) | 45 |
| CD30 | CD30 | 111 |
| CDAI | Clinical Disease Activity Index | 5 |
| CDC | Centers for Disease Control and Prevention | 829 |
| CDI | Clostridioides difficile infection | 118 |
| CEA | carcinoembryonic antigen | 102 |
| CETP | cholesteryl ester transfer protein | 16 |
| CGI-I | Clinical Global Impression-Improvement | 3 |
| CGI-S | Clinical Global Impression-Severity | 2 |
| CHA2DS2-VA | CHA2DS2-VA score | 8 |
| CHA2DS2-VASc | CHA2DS2-VASc score | 11 |
| CHADS2 | CHADS2 score | 1 |
| CHAMP | Comprehensive High-Level Activity Mobility Predictor | 24 |
| ChAT | choline acetyltransferase | 6 |
| Child-Pugh | Child-Pugh classification | 97 |
| CHT1 | high-affinity choline transporter 1 | 4 |
| CIN | cervical intraepithelial neoplasia | 172 |
| CIWA-Ar | Clinical Institute Withdrawal Assessment for Alcohol, revised | 23 |
| CK | creatine kinase | 612 |
| CK-MB | creatine kinase-MB | 91 |
| CKD | chronic kidney disease | 259 |
| CKD-MBD | chronic kidney disease-mineral and bone disorder | 22 |
| CLI | critical limb ischemia | 10 |
| CLIFT | Crithidia luciliae immunofluorescence test | 2 |
| CLSI | Clinical and Laboratory Standards Institute | 42 |
| CLTI | chronic limb-threatening ischemia | 19 |
| CML | chronic myeloid leukemia | 210 |
| CMV | cytomegalovirus | 299 |
| CNN | convolutional neural network | 9 |
| CO-RADS | COVID-19 Reporting and Data System | 3 |
| COMT | catechol-O-methyltransferase | 99 |
| CoNS | coagulase-negative staphylococci | 58 |
| COPD | chronic obstructive pulmonary disease | 418 |
| COVID-19 | coronavirus disease 2019 | 384 |
| COX | cyclooxygenase | 257 |
| COX-1 | cyclooxygenase-1 | 47 |
| COX-2 | cyclooxygenase-2 | 171 |
| CPT-I | carnitine palmitoyltransferase I | 5 |
| CPT-II | carnitine palmitoyltransferase II | 1 |
| CRAB | carbapenem-resistant Acinetobacter baumannii | 90 |
| CrAg | cryptococcal antigen | 24 |
| CRP | C-reactive protein | 366 |
| CRSWD | circadian rhythm sleep-wake disorder | 0 |
| CRT | cardiac resynchronization therapy | 43 |
| csDMARD | conventional synthetic disease-modifying antirheumatic drug | 43 |
| CSF | cerebrospinal fluid | 616 |
| CSWS | continuous spike-and-wave during slow-wave sleep | 5 |
| CT | computed tomography | 5912 |
| CTA | computed tomography angiography | 170 |
| CTCAE | Common Terminology Criteria for Adverse Events | 11 |
| CTCL | cutaneous T-cell lymphoma | 37 |
| CTL | cytotoxic T lymphocyte | 40 |
| cTNM | clinical TNM | 7 |
| CURB-65 | Confusion, Urea, Respiratory rate, Blood pressure, age 65 score | 25 |
| CVID | common variable immunodeficiency | 86 |
| CY-BOCS | Children's Yale-Brown Obsessive Compulsive Scale | 2 |
| CYP | cytochrome P450 | 357 |
| CYP11B1 | 11-beta-hydroxylase | 15 |
| CYP1A2 | cytochrome P450 1A2 | 127 |
| CYP2D6 | cytochrome P450 2D6 | 322 |
| CYP3A4 | cytochrome P450 3A4 | 857 |
| CYP450 | cytochrome P450 | 64 |
| DAA | direct-acting antiviral | 121 |
| DAG | diacylglycerol | 62 |
| DAMPs | damage-associated molecular patterns | 5 |
| DAPT | dual antiplatelet therapy | 64 |
| DAS28 | Disease Activity Score in 28 joints | 32 |
| DAT | direct antiglobulin test | 40 |
| DBT | digital breast tomosynthesis | 14 |
| DCIS | ductal carcinoma in situ | 123 |
| DEC | diethylcarbamazine | 64 |
| DEE-SWAS | developmental and/or epileptic encephalopathy with spike-wave activation in sleep | 7 |
| DFA | direct fluorescent antibody | 24 |
| dFLC | Difference between involved and uninvolved free light chains | 2 |
| DFNS | German Research Network on Neuropathic Pain | 2 |
| DHCA | dihydroxycholestanoic acid | 0 |
| DHEA | dehydroepiandrosterone | 185 |
| DHEA-S | DHEA sulfate | 46 |
| DHEAS | dehydroepiandrosterone sulfate | 23 |
| DHT | dihydrotestosterone | 79 |
| DIC | disseminated intravascular coagulation | 334 |
| DICOM | Digital Imaging and Communications in Medicine | 2 |
| DIHS | drug-induced hypersensitivity syndrome | 30 |
| DILI | drug-induced liver injury | 46 |
| DISI | dorsal intercalated segment instability | 2 |
| DKA | diabetic ketoacidosis | 339 |
| DLCO | diffusing capacity of the lung for carbon monoxide | 78 |
| DLMO | dim light melatonin onset | 2 |
| DLQI | Dermatology Life Quality Index | 21 |
| DMARD | disease-modifying antirheumatic drug | 129 |
| DMSA | dimercaptosuccinic acid | 49 |
| DMT1 | divalent metal transporter 1 (DMT1) | 2 |
| DNA | deoxyribonucleic acid | 3522 |
| DOAC | direct oral anticoagulant | 88 |
| DOTANOC | DOTANOC | 2 |
| DOTATATE | DOTATATE | 20 |
| DOTATOC | DOTATOC | 2 |
| DPP-4 | dipeptidyl peptidase-4 | 199 |
| DRESS | drug reaction with eosinophilia and systemic symptoms | 130 |
| DSM | Diagnostic and Statistical Manual of Mental Disorders | 64 |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition | 44 |
| DSWPD | delayed sleep-wake phase disorder | 1 |
| DTaP | diphtheria, tetanus, acellular pertussis vaccine | 38 |
| DTPA | diethylenetriaminepentaacetic acid | 10 |
| DTR | difficult-to-treat resistance | 32 |
| DVT | deep vein thrombosis | 160 |
| DWI | diffusion-weighted imaging | 30 |
| DXA | dual-energy X-ray absorptiometry | 43 |
| EASI | Eczema Area and Severity Index | 15 |
| EASI-50 | EASI 50 response | 2 |
| EASI-75 | EASI 75 response | 2 |
| EASI-90 | EASI 90 response | 2 |
| EASL | European Association for the Study of the Liver | 170 |
| EAU | European Association of Urology | 216 |
| EBV | Epstein-Barr virus | 256 |
| ECCO | European Crohn's and Colitis Organisation | 29 |
| ECIBC | European Commission Initiative on Breast Cancer | 4 |
| ECM | extracellular matrix | 90 |
| ECMO | extracorporeal membrane oxygenation | 189 |
| ECOG PS | ECOG performance status | 9 |
| EDTA | ethylenediaminetetraacetic acid | 55 |
| EE-SWAS | epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) | 20 |
| EEE | eastern equine encephalitis | 13 |
| EEEV | eastern equine encephalitis virus | 5 |
| eFAST | extended focused assessment with sonography for trauma | 50 |
| eGFR | estimated glomerular filtration rate | 243 |
| EIA | enzyme immunoassay | 111 |
| EITB | enzyme-linked immunoelectrotransfer blot | 2 |
| EKC | epidemic keratoconjunctivitis | 10 |
| ELISA | enzyme-linked immunosorbent assay | 353 |
| EMA-CO | etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine | 15 |
| ENaC | epithelial sodium channel (ENaC) | 52 |
| EOSS | Edmonton Obesity Staging System | 15 |
| EOSS-P | pediatric Edmonton Obesity Staging System | 1 |
| EpCAM | epithelial cell adhesion molecule | 2 |
| EPCAM | epithelial cell adhesion molecule | 5 |
| EPO | erythropoietin | 86 |
| ERCP | endoscopic retrograde cholangiopancreatography | 135 |
| EREFS | EREFS (EoE Endoscopic Reference Score) | 2 |
| ERP | exposure and response prevention | 37 |
| ERS | European Respiratory Society | 23 |
| ESBL | extended-spectrum β-lactamase | 121 |
| ESC | European Society of Cardiology | 1036 |
| ESCMID | European Society of Clinical Microbiology and Infectious Diseases | 70 |
| ESES | electrical status epilepticus in sleep | 5 |
| ESH | European Society of Hypertension | 18 |
| ESR | erythrocyte sedimentation rate | 128 |
| ESST | Edgren Side Step Test | 5 |
| ESUR | European Society of Urogenital Radiology | 43 |
| EU | European Union | 2716 |
| EUCAST | European Committee on Antimicrobial Susceptibility Testing | 31 |
| EULAR | European Alliance of Associations for Rheumatology | 627 |
| EUS-FNA | endoscopic ultrasound-guided fine-needle aspiration | 10 |
| EVALI | e-cigarette or vaping product use-associated lung injury | 11 |
| EVAR | endovascular aneurysm repair | 19 |
| EWGSOP2 | European Working Group on Sarcopenia in Older People 2 | 11 |
| FAC | Functional Ambulation Category | 33 |
| FAD | flavin adenine dinucleotide | 49 |
| FcRn | neonatal Fc receptor | 39 |
| FDA | Food and Drug Administration | 1590 |
| FDG | fluorodeoxyglucose | 429 |
| FDG-PET | FDG PET | 73 |
| FDG-PET/CT | FDG PET/CT | 25 |
| FDP | fibrin/fibrinogen degradation products | 29 |
| FdUMP | FdUMP (fluorodeoxyuridine monophosphate) | 1 |
| FESD | flexible endoscopic septum division | 1 |
| FEV1 | forced expiratory volume in one second | 77 |
| FEV₁ | forced expiratory volume in one second | 85 |
| FGF23 | fibroblast growth factor 23 | 62 |
| FGFR | fibroblast growth factor receptor | 143 |
| FIB-4 | Fibrosis-4 index | 52 |
| FIM | Functional Independence Measure | 25 |
| FISH | fluorescence in situ hybridization | 121 |
| FKBP-12 | FK506-binding protein 12 | 4 |
| FLAIR | fluid-attenuated inversion recovery (FLAIR) | 73 |
| FMT | fecal microbiota transplantation | 41 |
| FNA | fine-needle aspiration | 92 |
| FNAB | fine-needle aspiration biopsy | 4 |
| FODMAP | fermentable oligosaccharides, disaccharides, monosaccharides and polyols | 26 |
| FOLFIRI | FOLFIRI regimen | 14 |
| FOLFIRINOX | FOLFIRINOX regimen | 29 |
| FOLFOX | FOLFOX regimen | 40 |
| FRAX | Fracture Risk Assessment Tool | 65 |
| FSH | follicle-stimulating hormone | 681 |
| FT3 | free triiodothyronine | 13 |
| FT4 | free thyroxine | 106 |
| FTA-ABS | fluorescent treponemal antibody absorption | 12 |
| FTCD | Fagerström Test for Cigarette Dependence | 4 |
| FTND | Fagerström Test for Nicotine Dependence | 6 |
| FTND-ST | Fagerström Test for Nicotine Dependence-Smokeless Tobacco | 1 |
| FTQ | Fagerström Tolerance Questionnaire | 2 |
| FVC | forced vital capacity | 148 |
| FXR | farnesoid X receptor | 43 |
| G-CSF | granulocyte colony-stimulating factor | 57 |
| G6PD | glucose-6-phosphate dehydrogenase | 345 |
| GABA | gamma-aminobutyric acid | 568 |
| GAE | granulomatous amebic encephalitis | 12 |
| GAN | generative adversarial network | 10 |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | 4 |
| GARFT | glycinamide ribonucleotide formyltransferase | 12 |
| Gb3 | globotriaosylceramide (Gb3) | 24 |
| GC-MS | gas chromatography-mass spectrometry | 2 |
| GCS | Glasgow Coma Scale | 111 |
| GDH | glutamate dehydrogenase | 42 |
| GEP-NET | gastroenteropancreatic neuroendocrine tumor | 6 |
| GFR | glomerular filtration rate | 406 |
| GGT | gamma-glutamyl transferase | 71 |
| GINA | Global Initiative for Asthma | 132 |
| GIST | gastrointestinal stromal tumor | 170 |
| GLASS | Global Limb Anatomic Staging System | 2 |
| GLP-1 | glucagon-like peptide-1 | 413 |
| GLUT1 | glucose transporter 1 | 68 |
| GLUT2 | glucose transporter 2 | 21 |
| GLUT4 | glucose transporter 4 | 74 |
| glypican-3 | glypican-3 | 8 |
| GnRH | gonadotropin-releasing hormone | 446 |
| GOLD | Global Initiative for Chronic Obstructive Lung Disease | 272 |
| GOT | glutamic oxaloacetic transaminase | 5 |
| GPIb | glycoprotein Ib | 31 |
| GPIIb/IIIa | glycoprotein IIb/IIIa | 12 |
| GPR109A | niacin receptor GPR109A | 4 |
| GPRC5D | GPRC5D | 24 |
| GPT | glutamic pyruvic transaminase | 4 |
| GPU | graphics processing unit | 2 |
| GTR/STR | gross total resection/subtotal resection | 0 |
| GVHD | graft-versus-host disease (GVHD) | 234 |
| HAART | highly active antiretroviral therapy | 6 |
| HACEK | Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella | 55 |
| HAdV | human adenovirus | 13 |
| HAM/TSP | HTLV-1-associated myelopathy/tropical spastic paraparesis | 31 |
| HAS-BLED | HAS-BLED score | 1 |
| HAT | human African trypanosomiasis | 20 |
| HAV | hepatitis A virus | 68 |
| HbA1c | glycated haemoglobin A1c | 532 |
| HbA2 | hemoglobin A2 | 33 |
| HbF | fetal hemoglobin | 64 |
| HBV | hepatitis B virus | 914 |
| HCC | hepatocellular carcinoma | 134 |
| hCG | human chorionic gonadotropin | 320 |
| HCV | hepatitis C virus | 518 |
| HDAC | histone deacetylase | 47 |
| HDL | high-density lipoprotein | 233 |
| HDL-C | HDL cholesterol | 42 |
| HDP | hydroxymethylene diphosphonate | 5 |
| HDU | high-dependency unit | 2 |
| HELLP | haemolysis, elevated liver enzymes, low platelets | 101 |
| HER2 | human epidermal growth factor receptor 2 | 541 |
| hERG | human ether-a-go-go-related gene | 18 |
| HEV | hepatitis E virus | 74 |
| HFmrEF | heart failure with mildly reduced ejection fraction | 104 |
| HFpEF | heart failure with preserved ejection fraction | 22 |
| HFrEF | heart failure with reduced ejection fraction | 73 |
| HGPRT | hypoxanthine-guanine phosphoribosyltransferase | 47 |
| HHS | hyperosmolar hyperglycemic state | 108 |
| HHV6/7 | human herpesvirus 6/7 | 1 |
| HIE | hypoxic-ischemic encephalopathy | 23 |
| HIF | hypoxia-inducible factor | 266 |
| HIV | human immunodeficiency virus | 983 |
| HIV-1 | human immunodeficiency virus type 1 | 237 |
| HIV-2 | human immunodeficiency virus type 2 | 62 |
| HLA | human leukocyte antigen | 983 |
| HLA-B27 | human leukocyte antigen B27 | 129 |
| HMG-CoA | 3-hydroxy-3-methylglutaryl coenzyme A | 127 |
| HMGB1 | high mobility group box 1 | 4 |
| HoFH | homozygous familial hypercholesterolemia | 4 |
| HPA | hypothalamic-pituitary-adrenal | 104 |
| HPIV | human parainfluenza virus | 14 |
| HPLC | high-performance liquid chromatography | 15 |
| HPV | human papillomavirus | 996 |
| HRCT | high-resolution computed tomography | 52 |
| hrHPV | high-risk human papillomavirus | 51 |
| HRP2 | histidine-rich protein 2 | 7 |
| HSCT | hematopoietic stem cell transplantation | 71 |
| HSI | Heaviness of Smoking Index | 5 |
| HSIL | high-grade squamous intraepithelial lesion | 87 |
| HSV | herpes simplex virus | 613 |
| HSV-1 | herpes simplex virus type 1 | 111 |
| HSV-2 | herpes simplex virus type 2 | 78 |
| HTLV-1 | human T-cell leukemia virus type 1 | 127 |
| htTKV | height-adjusted total kidney volume | 11 |
| HU | Hounsfield unit | 216 |
| HUS | hemolytic uremic syndrome | 255 |
| HVA | homovanillic acid (HVA) | 11 |
| IABP | intra-aortic balloon pump | 41 |
| IADL | instrumental activities of daily living | 9 |
| IASP | International Association for the Study of Pain | 38 |
| IAT | Illinois Agility Test | 7 |
| IBD | inflammatory bowel disease | 188 |
| IBS | irritable bowel syndrome | 195 |
| ICANS | immune effector cell-associated neurotoxicity syndrome (ICANS) | 58 |
| ICBD | International Criteria for Behçet's Disease | 16 |
| ICSH | International Council for Standardization in Haematology | 8 |
| ICTV | International Committee on Taxonomy of Viruses | 72 |
| ICU | intensive care unit | 179 |
| IDH | isocitrate dehydrogenase | 222 |
| IDL | intermediate-density lipoprotein | 20 |
| IDSA | Infectious Diseases Society of America | 431 |
| IE | infective endocarditis | 150 |
| IENFD | intraepidermal nerve fiber density | 12 |
| IFA | immunofluorescence assay | 21 |
| IgG ELISA | IgG enzyme-linked immunosorbent assay | 14 |
| IgG1 | immunoglobulin G1 | 50 |
| IgG2 | immunoglobulin G2 | 12 |
| IgG4 | immunoglobulin G4 | 148 |
| IGRA | interferon-gamma release assay | 24 |
| IKr | rapid delayed rectifier potassium current | 2 |
| IL-13 | interleukin-13 | 131 |
| IL-2 | interleukin-2 | 202 |
| IL-31 | interleukin-31 | 8 |
| IL-31RA | IL-31 receptor A | 6 |
| IL-4 | interleukin-4 | 132 |
| IL-4Rα | IL-4 receptor alpha | 65 |
| IL-5Rα | IL-5 receptor alpha | 10 |
| ILD-GAP | ILD-GAP index | 2 |
| IMiD | immunomodulatory drug | 39 |
| iNPH | idiopathic normal pressure hydrocephalus | 33 |
| INR | international normalized ratio | 255 |
| INSTI | integrase strand transfer inhibitor | 52 |
| IOTA | International Ovarian Tumor Analysis | 6 |
| IP3 | inositol 1,4,5-trisphosphate | 49 |
| IPF | idiopathic pulmonary fibrosis | 38 |
| IPI | International Prognostic Index | 44 |
| IRDS | infant respiratory distress syndrome | 15 |
| IRI | immunoreactive insulin | 115 |
| IRIS | immune reconstitution inflammatory syndrome | 92 |
| IRS | insulin receptor substrate | 102 |
| ISI | international sensitivity index | 8 |
| ISTH-BAT | ISTH Bleeding Assessment Tool | 7 |
| ISWRD | irregular sleep-wake rhythm disorder | 1 |
| ITP | immune thrombocytopenia | 80 |
| IUD | intrauterine device | 126 |
| IVIG | intravenous immunoglobulin | 308 |
| IVR | interventional radiology | 46 |
| JAK | Janus kinase | 375 |
| JAK1 | Janus kinase 1 | 59 |
| JAK2 | Janus kinase 2 gene | 81 |
| JAK3 | Janus kinase 3 | 23 |
| JTc | corrected JT interval | 1 |
| K-level | Medicare Functional Classification Level | 38 |
| KATP | ATP-sensitive potassium channel | 29 |
| KCNH2 | KCNH2 gene | 3 |
| KCNQ1 | KCNQ1 gene | 6 |
| KCS | keratoconjunctivitis sicca | 5 |
| KDAC | Kienbock disease advanced collapse | 3 |
| KDIGO | Kidney Disease: Improving Global Outcomes | 108 |
| Keap1 | Kelch-like ECH-associated protein 1 | 1 |
| KES | Klebsiella-Enterobacter-Serratia | 21 |
| Ki-67 | Ki-67 proliferation index | 50 |
| KOH | potassium hydroxide | 203 |
| KPC | Klebsiella pneumoniae carbapenemase | 75 |
| KPS | Karnofsky Performance Status | 4 |
| KSHV | Kaposi's sarcoma-associated herpesvirus | 47 |
| LABA | long-acting beta2-agonist | 110 |
| LADA | latent autoimmune diabetes in adults | 39 |
| LAMA | long-acting muscarinic antagonist | 91 |
| LAMP | loop-mediated isothermal amplification | 3 |
| larva currens | larva currens | 3 |
| LAST | Lower Anogenital Squamous Terminology | 23 |
| LC-MS/MS | liquid chromatography-tandem mass spectrometry | 23 |
| LCAT | lecithin-cholesterol acyltransferase | 55 |
| LCDD | light chain deposition disease | 12 |
| LDH | lactate dehydrogenase | 294 |
| LDL | low-density lipoprotein | 522 |
| LDL-C | low-density lipoprotein cholesterol | 554 |
| LEEP | loop electrosurgical excision procedure | 3 |
| LFA | lateral flow assay | 18 |
| LGMD | limb-girdle muscular dystrophy | 35 |
| LGV | lymphogranuloma venereum | 77 |
| LH | luteinizing hormone | 649 |
| LI-RADS | Liver Imaging Reporting and Data System | 5 |
| LKS | Landau-Kleffner syndrome (LKS) | 0 |
| LL-37 | cathelicidin LL-37 | 6 |
| Lp(a) | lipoprotein(a) | 12 |
| LPL | lipoprotein lipase | 61 |
| LpX | lipoprotein X | 4 |
| LQT1 | long QT syndrome type 1 | 1 |
| LQT2 | long QT syndrome type 2 | 1 |
| LQT3 | long QT syndrome type 3 | 1 |
| LSIL | low-grade squamous intraepithelial lesion | 56 |
| LTRA | leukotriene receptor antagonist | 21 |
| LVAD | left ventricular assist device | 26 |
| LVEF | left ventricular ejection fraction | 165 |
| LXR | liver X receptor | 23 |
| lyso-Gb3 | globotriaosylsphingosine (lyso-Gb3) | 8 |
| M4Eo | acute myelomonocytic leukemia with eosinophilia | 1 |
| MAA | macroaggregated albumin | 6 |
| MAC | Mycobacterium avium complex | 243 |
| MAG3 | mercaptoacetyltriglycine | 15 |
| MALDI-TOF | matrix-assisted laser desorption/ionization time-of-flight | 31 |
| MALDI-TOF MS | matrix-assisted laser desorption/ionization time-of-flight mass spectrometry | 4 |
| MAO | monoamine oxidase | 684 |
| MAO-A | monoamine oxidase A | 43 |
| MAO-B | monoamine oxidase B | 42 |
| MART | maintenance and reliever therapy | 48 |
| MASLD | metabolic dysfunction-associated steatotic liver disease | 140 |
| MASP-2 | mannan-binding lectin serine protease 2 | 11 |
| MCAD | medium-chain acyl-CoA dehydrogenase | 63 |
| MCHC | mean corpuscular hemoglobin concentration | 13 |
| MCI | mild cognitive impairment | 25 |
| MCID | minimal clinically important difference | 2 |
| MCV | mean corpuscular volume | 133 |
| MDA | mass drug administration | 11 |
| MDC | minimal detectable change | 10 |
| MDMA | 3,4-methylenedioxymethamphetamine (MDMA) | 8 |
| MDP | methylene diphosphonate | 13 |
| MDR-TB | multidrug-resistant tuberculosis | 22 |
| MDS | myelodysplastic syndrome | 115 |
| MELAS | mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) | 13 |
| MELD 3.0 | Model for End-Stage Liver Disease 3.0 | 8 |
| MELD-Na | Model for End-Stage Liver Disease-Sodium | 3 |
| MEN1 | multiple endocrine neoplasia type 1 | 43 |
| MEN2 | multiple endocrine neoplasia type 2 | 86 |
| MenABCWY | MenABCWY vaccine | 5 |
| MenACWY | MenACWY vaccine | 9 |
| MenB | MenB vaccine | 9 |
| MERRF | myoclonic epilepsy with ragged red fibers (MERRF) | 13 |
| MEWS | Modified Early Warning Score | 7 |
| MF/SS | mycosis fungoides / Sezary syndrome | 2 |
| mFARS | modified Friedreich Ataxia Rating Scale | 2 |
| MFCL | Medicare Functional Classification Level | 0 |
| mGPS | modified Glasgow Prognostic Score | 13 |
| MGRS | monoclonal gammopathy of renal significance | 9 |
| MGUS | monoclonal gammopathy of undetermined significance | 36 |
| MHRA | Medicines and Healthcare products Regulatory Agency | 66 |
| MIBG | metaiodobenzylguanidine | 90 |
| MIBI | methoxyisobutylisonitrile | 4 |
| MIC | minimum inhibitory concentration | 302 |
| MIC90 | minimum inhibitory concentration for 90% of isolates | 11 |
| MIDD | monoclonal immunoglobulin deposition disease | 10 |
| MINOCA | myocardial infarction with non-obstructive coronary arteries | 20 |
| Mirels score | Mirels score | 2 |
| MLO | mediolateral oblique | 2 |
| MLPA | multiplex ligation-dependent probe amplification (MLPA) | 15 |
| MMAE | monomethyl auristatin E | 22 |
| MMP | matrix metalloproteinase | 113 |
| mMRC | modified Medical Research Council dyspnea scale | 32 |
| MMSE | Mini-Mental State Examination | 27 |
| MMT | manual muscle testing | 0 |
| MoCA | Montreal Cognitive Assessment | 24 |
| MODY | maturity-onset diabetes of the young | 42 |
| Motherisk-PUQE | Motherisk Pregnancy-Unique Quantification of Emesis and Nausea | 1 |
| MPL | MPL gene | 27 |
| MPNST | malignant peripheral nerve sheath tumor | 55 |
| MPO-ANCA | myeloperoxidase ANCA | 23 |
| MRCP | magnetic resonance cholangiopancreatography | 100 |
| MRI | magnetic resonance imaging | 1072 |
| MRI FLAIR | FLAIR MRI | 1 |
| MRSA | methicillin-resistant Staphylococcus aureus | 320 |
| MSM | men who have sex with men | 28 |
| MTHFR | methylenetetrahydrofolate reductase | 39 |
| MTX | methotrexate | 197 |
| MUAC | mid-upper arm circumference | 3 |
| MutLα | MutL alpha complex | 1 |
| MutSα | MutS alpha complex | 2 |
| N24SWD | non-24-hour sleep-wake rhythm disorder | 3 |
| Na/K ATPase | sodium-potassium ATPase | 1 |
| Na⁺/K⁺-ATPase | sodium-potassium ATPase | 30 |
| NAAT | nucleic acid amplification test | 181 |
| NADPH | nicotinamide adenine dinucleotide phosphate (reduced) | 152 |
| NAFLD | nonalcoholic fatty liver disease | 98 |
| NALD | neonatal adrenoleukodystrophy | 2 |
| NAPQI | N-acetyl-p-benzoquinone imine | 43 |
| NASCET | North American Symptomatic Carotid Endarterectomy Trial | 14 |
| NCCN-IPI | NCCN International Prognostic Index | 5 |
| NDM | New Delhi metallo-β-lactamase | 31 |
| NDMA | N-nitrosodimethylamine (NDMA) | 12 |
| NEAR | nicking enzyme amplification reaction | 4 |
| NERD | nonerosive reflux disease | 4 |
| Neuropad | Neuropad test | 13 |
| NEWS/NEWS2 | National Early Warning Score / NEWS2 | 7 |
| NEXUS | National Emergency X-Radiography Utilization Study | 2 |
| NFAT | nuclear factor of activated T cells | 6 |
| NHANES III | Third National Health and Nutrition Examination Survey | 2 |
| NICE | National Institute for Health and Care Excellence | 374 |
| NIFTP | noninvasive follicular thyroid neoplasm with papillary-like nuclear features | 8 |
| NIHSS | National Institutes of Health Stroke Scale | 26 |
| NIS | sodium-iodide symporter | 36 |
| NNRTI | non-nucleoside reverse transcriptase inhibitor | 56 |
| NNT | number needed to treat | 31 |
| non-HDL-C | non-HDL cholesterol | 11 |
| NPC1L1 | Niemann-Pick C1-like 1 | 32 |
| NPH | neutral protamine Hagedorn | 46 |
| NPO | nil per os | 2 |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | 1 |
| nr-axSpA | nonradiographic axial spondyloarthritis | 1 |
| Nrf2 | nuclear factor erythroid 2-related factor 2 | 6 |
| NRTI | nucleoside reverse transcriptase inhibitor | 92 |
| NSAID | nonsteroidal anti-inflammatory drug | 885 |
| NSAIDs | nonsteroidal anti-inflammatory drugs | 483 |
| NSCLC | non-small cell lung cancer | 116 |
| NSF | nephrogenic systemic fibrosis | 66 |
| NSIAD | nephrogenic syndrome of inappropriate antidiuresis (NSIAD) | 1 |
| NSTE-ACS | non-ST-elevation acute coronary syndrome | 23 |
| NSTEMI | non-ST-elevation myocardial infarction | 18 |
| NT-proBNP | N-terminal pro-B-type natriuretic peptide | 34 |
| NTM | nontuberculous mycobacteria | 18 |
| NVP | nausea and vomiting of pregnancy | 10 |
| NYHA | New York Heart Association | 48 |
| O-RADS | Ovarian-Adnexal Imaging Reporting and Data System | 40 |
| O-RADS US | Ovarian-Adnexal Reporting and Data System Ultrasound | 10 |
| OAB | overactive bladder | 24 |
| OCT4 | OCT4 (POU5F1) | 7 |
| OGTT | oral glucose tolerance test | 142 |
| os acromiale | os acromiale | 0 |
| OSMR | oncostatin M receptor beta | 1 |
| Oxford Shoulder Score | Oxford Shoulder Score | 2 |
| P-CAB | potassium-competitive acid blocker | 35 |
| P2Y1 | P2Y1 receptor | 1 |
| P2Y12 | P2Y12 receptor | 38 |
| PABA | para-aminobenzoic acid, PABA | 13 |
| PaCO2 | arterial carbon dioxide tension | 45 |
| PAD | peripheral artery disease | 50 |
| PAI-1 | plasminogen activator inhibitor-1 | 35 |
| PAIR | puncture, aspiration, injection, re-aspiration | 29 |
| PAMORA | peripherally acting mu-opioid receptor antagonist | 14 |
| PaO2 | arterial oxygen partial pressure | 22 |
| PaO2/FiO2 | PaO2/FiO2 ratio | 10 |
| PAPS | 3'-phosphoadenosine-5'-phosphosulfate | 3 |
| PASI | Psoriasis Area and Severity Index | 40 |
| PBD | peroxisome biogenesis disorder | 4 |
| PBP | penicillin-binding protein | 131 |
| PBP2 | penicillin-binding protein 2 | 38 |
| PC-AKI | post-contrast acute kidney injury | 2 |
| PC1/3 | prohormone convertase 1/3 | 1 |
| PC2 | prohormone convertase 2 | 1 |
| PC20 | provocative concentration causing a 20% fall in FEV1 | 9 |
| PCA | posterior cerebral artery | 20 |
| PCA-1 | Purkinje cell antibody 1 | 1 |
| PCA3 | prostate cancer antigen 3 | 2 |
| PCAB | potassium-competitive acid blocker | 9 |
| PCI | percutaneous coronary intervention | 123 |
| PCR | polymerase chain reaction | 1432 |
| PCSK9 | proprotein convertase subtilisin/kexin type 9 | 224 |
| PD20 | provocative dose causing a 20% fall in FEV1 | 13 |
| PDE5 | phosphodiesterase type 5 | 281 |
| PDGF | platelet-derived growth factor | 86 |
| PDGFR | platelet-derived growth factor receptor | 111 |
| PDGFRA | platelet-derived growth factor receptor alpha (PDGFRA) | 60 |
| PDH | pyruvate dehydrogenase | 23 |
| PEComa | perivascular epithelioid cell tumor (PEComa) | 5 |
| PEF | peak expiratory flow | 58 |
| PEPCK | phosphoenolpyruvate carboxykinase | 10 |
| PERCIST | PET Response Criteria in Solid Tumors | 19 |
| PERCIST 1.0 | PET Response Criteria in Solid Tumors 1.0 | 1 |
| PERM | progressive encephalomyelitis with rigidity and myoclonus | 3 |
| PET | positron emission tomography | 426 |
| PET-CT | positron emission tomography–computed tomography | 173 |
| PET/CT | positron emission tomography–computed tomography | 275 |
| PfEMP1 | Plasmodium falciparum erythrocyte membrane protein 1 | 2 |
| PFK-1 | phosphofructokinase-1 | 1 |
| PGI2 | prostaglandin I2 | 27 |
| PHMB | polyhexamethylene biguanide | 12 |
| PI-RADS | Prostate Imaging Reporting and Data System | 8 |
| PI3K | phosphoinositide 3-kinase | 144 |
| PICA | posterior inferior cerebellar artery | 5 |
| Pierre Robin sequence | Pierre Robin sequence | 16 |
| PIP2 | phosphatidylinositol 4,5-bisphosphate | 28 |
| PIP3 | phosphatidylinositol 3,4,5-trisphosphate | 25 |
| PKM2 | pyruvate kinase M2 | 4 |
| PKU | phenylketonuria | 98 |
| PLP | pyridoxal 5'-phosphate | 44 |
| PMBC | percutaneous mitral balloon commissurotomy | 23 |
| PML | progressive multifocal leukoencephalopathy | 221 |
| POCUS | point-of-care ultrasound | 43 |
| POEM | Patient-Oriented Eczema Measure | 38 |
| PORT score | Pneumonia Patient Outcomes Research Team score | 1 |
| PPAR | peroxisome proliferator-activated receptor | 136 |
| PPARα | peroxisome proliferator-activated receptor alpha | 36 |
| PPE | personal protective equipment | 10 |
| PPF | progressive pulmonary fibrosis | 38 |
| PPGL | pheochromocytoma and paraganglioma | 39 |
| PPI | proton pump inhibitor | 303 |
| PPP | pentose phosphate pathway | 14 |
| PR3-ANCA | proteinase 3-ANCA | 24 |
| pre-XDR-TB | pre-extensively drug-resistant tuberculosis | 6 |
| PrEP | pre-exposure prophylaxis | 93 |
| PREVENT-ASCVD | Predicting Risk of cardiovascular disease EVENTs — atherosclerotic cardiovascular disease | 2 |
| PREVENT-CVD | Predicting Risk of cardiovascular disease EVENTs — cardiovascular disease | 4 |
| PREVENT-HF | Predicting Risk of cardiovascular disease EVENTs — heart failure | 1 |
| PRO | patient-reported outcome | 105 |
| PRPP | phosphoribosyl pyrophosphate | 15 |
| PRRT | peptide receptor radionuclide therapy | 14 |
| PSA | prostate-specific antigen | 293 |
| PSI | Pneumonia Severity Index | 25 |
| PSMA | prostate-specific membrane antigen | 62 |
| PSMA-11 | PSMA-targeting ligand 11 (gozetotide) | 2 |
| PSMA-617 | PSMA-targeting ligand 617 (vipivotide tetraxetan) | 13 |
| PSMA-PET | PSMA PET | 2 |
| PSTT | placental site trophoblastic tumor | 12 |
| PT | prothrombin time | 1065 |
| PT-INR | prothrombin time-international normalized ratio | 11 |
| PTEN | phosphatase and tensin homolog | 108 |
| PTH | parathyroid hormone | 330 |
| pTNM | pathological TNM | 18 |
| PTU | propylthiouracil | 140 |
| PUQE-24 | 24-hour Pregnancy-Unique Quantification of Emesis and Nausea | 6 |
| PUVA | psoralen plus ultraviolet A | 39 |
| PXR | pregnane X receptor | 29 |
| QOL | quality of life | 90 |
| QSART | quantitative sudomotor axon reflex test | 63 |
| qSOFA | quick Sequential Organ Failure Assessment | 27 |
| QST | quantitative sensory testing | 20 |
| QTc | corrected QT interval | 42 |
| QTcF | Fridericia-corrected QT interval (QTcF) | 7 |
| R-IPI | Revised International Prognostic Index | 2 |
| RAAS | renin-angiotensin-aldosterone system | 192 |
| RAGE | receptor for advanced glycation end products | 5 |
| RAPD | relative afferent pupillary defect | 61 |
| RCDP | rhizomelic chondrodysplasia punctata | 29 |
| RDT | rapid diagnostic test | 4 |
| RDW | red cell distribution width | 20 |
| REMS | Risk Evaluation and Mitigation Strategy | 46 |
| riMLF | rostral interstitial nucleus of the MLF | 1 |
| RNA | ribonucleic acid | 1534 |
| ROC | receiver operating characteristic | 114 |
| RPGN | rapidly progressive glomerulonephritis | 68 |
| RPR | rapid plasma reagin | 54 |
| RR-TB | rifampicin-resistant tuberculosis | 29 |
| RSNA | Radiological Society of North America | 6 |
| RSV | respiratory syncytial virus | 93 |
| RT-PCR | reverse transcription polymerase chain reaction | 150 |
| RTOG | Radiation Therapy Oncology Group | 12 |
| RUSP | recommended Uniform Screening Panel | 4 |
| rWFNS | reassessed WFNS grade | 1 |
| SABA | short-acting β2-agonist | 273 |
| SALL4 | SALL4 (spalt-like transcription factor 4) | 20 |
| SAMA | short-acting muscarinic antagonist | 37 |
| SAMHSA | Substance Abuse and Mental Health Services Administration | 2 |
| Sanz risk score | Sanz risk score | 4 |
| SBMA | spinal and bulbar muscular atrophy (SBMA) | 3 |
| SCC-KA | squamous cell carcinoma, keratoacanthoma type | 3 |
| SCCT | Society of Cardiovascular Computed Tomography | 6 |
| SCN5A | SCN5A gene | 3 |
| SCORAD | SCORing Atopic Dermatitis | 24 |
| SCORE2 | Systematic COronary Risk Evaluation 2 | 13 |
| SCORE2-OP | SCORE2-Older Persons | 12 |
| SCORTEN | SCORTEN | 17 |
| SDS | sodium dodecyl sulfate | 48 |
| SDS-PAGE | sodium dodecyl sulfate-polyacrylamide gel electrophoresis | 18 |
| Sepsis-3 | Third International Consensus Definitions for Sepsis and Septic Shock | 4 |
| SERM | selective estrogen receptor modulator | 43 |
| SGLT1 | sodium-glucose cotransporter 1 | 43 |
| SGLT2 | sodium-glucose cotransporter 2 | 515 |
| SHEA | Society for Healthcare Epidemiology of America | 82 |
| SIADH | syndrome of inappropriate antidiuretic hormone secretion | 88 |
| SIRS | systemic inflammatory response syndrome | 50 |
| SJC28 | 28-joint swollen joint count | 4 |
| SJS/TEN | Stevens-Johnson syndrome/toxic epidermal necrolysis | 99 |
| SLAC | scapholunate advanced collapse | 6 |
| SLNB | sentinel lymph node biopsy | 12 |
| SLS | single-leg stance | 9 |
| SMA | superior mesenteric artery | 159 |
| SMA/SMV | superior mesenteric artery/superior mesenteric vein | 1 |
| SNRI | serotonin-noradrenaline reuptake inhibitor | 221 |
| SpA | spondyloarthritis | 53 |
| SPECT | single-photon emission computed tomography | 95 |
| SPECT/CT | SPECT/CT | 7 |
| SpO2 | peripheral oxygen saturation | 67 |
| SPPB | Short Physical Performance Battery | 1 |
| SPS-plus | stiff-person syndrome plus | 11 |
| SREBP | sterol regulatory element-binding protein | 49 |
| SSc-ILD | systemic sclerosis-associated interstitial lung disease | 9 |
| SSG | sodium stibogluconate | 20 |
| SSR | sympathetic skin response | 274 |
| SSRI | selective serotonin reuptake inhibitor | 254 |
| SSTR2 | somatostatin receptor subtype 2 | 4 |
| StAR | steroidogenic acute regulatory protein | 19 |
| STAT3 | signal transducer and activator of transcription 3 (STAT3) | 35 |
| STEADI | Stopping Elderly Accidents, Deaths, and Injuries | 2 |
| STEMI | ST-elevation myocardial infarction | 72 |
| STI | sexually transmitted infection | 96 |
| STIR | short tau inversion recovery | 3 |
| SULT1A1 | sulfotransferase 1A1 | 0 |
| SUV | standardized uptake value | 25 |
| SUVmax | maximum standardized uptake value | 4 |
| SUVmean | mean standardized uptake value | 2 |
| SV40 | simian virus 40 | 7 |
| SVR12 | sustained virologic response at 12 weeks | 7 |
| SWI | susceptibility-weighted imaging | 48 |
| T-ACE | T-ACE questionnaire | 4 |
| T3SS | type III secretion system | 25 |
| TA-TMA | transplant-associated thrombotic microangiopathy | 38 |
| TAFI | thrombin-activatable fibrinolysis inhibitor | 18 |
| TBI | toe-brachial index | 27 |
| TBSRTC | The Bethesda System for Reporting Thyroid Cytopathology | 1 |
| Tc-99m | technetium-99m | 3 |
| TcPO2 | transcutaneous oxygen pressure | 28 |
| Tdap | tetanus, diphtheria, acellular pertussis vaccine | 49 |
| TdP | torsades de pointes | 74 |
| TENS | transcutaneous electrical nerve stimulation | 2 |
| TEVAR | thoracic endovascular aortic repair | 28 |
| TFPI | tissue factor pathway inhibitor | 62 |
| TGF-β | transforming growth factor-beta | 92 |
| THA | total hip arthroplasty | 23 |
| THCA | trihydroxycholestanoic acid | 0 |
| THF | tetrahydrofolate | 36 |
| TI-RADS | Thyroid Imaging Reporting and Data System | 15 |
| TIA | transient ischemic attack | 51 |
| TIG | tetanus immune globulin | 28 |
| TIMP | tissue inhibitor of metalloproteinases | 26 |
| TIPS | transjugular intrahepatic portosystemic shunt | 40 |
| Tis | carcinoma in situ | 37 |
| TJC28 | 28-joint tender joint count | 4 |
| TKI | tyrosine kinase inhibitor | 198 |
| TMA | thrombotic microangiopathy | 56 |
| TmP/GFR | tubular maximum phosphate reabsorption per glomerular filtration rate | 1 |
| TNF | tumour necrosis factor | 884 |
| TNF-α | tumor necrosis factor-alpha | 144 |
| TNM | tumor, node, metastasis | 385 |
| Torsade de pointes | torsades de pointes | 2 |
| tPA | tissue plasminogen activator | 88 |
| TPHA | Treponema pallidum hemagglutination assay | 19 |
| TPO | thyroid peroxidase | 148 |
| TPPA | Treponema pallidum particle agglutination | 19 |
| TRAPS | TNF receptor-associated periodic syndrome (TRAPS) | 2 |
| TRH | thyrotropin-releasing hormone | 57 |
| TROPIQUE | TROPIQUE study | 2 |
| TRPV1 | transient receptor potential vanilloid 1 | 7 |
| TS1 | thyroid storm 1 | 109 |
| TS2 | thyroid storm 2 | 6 |
| TSAT | transferrin saturation | 100 |
| tsDMARD | targeted synthetic disease-modifying antirheumatic drug | 10 |
| TSH | thyroid-stimulating hormone | 766 |
| TTP | thrombotic thrombocytopenic purpura | 143 |
| TUG | Timed Up and Go test | 22 |
| TURP | transurethral resection of the prostate | 23 |
| TWEAK | TWEAK questionnaire | 4 |
| TXA2 | thromboxane A2 | 31 |
| TYK2 | tyrosine kinase 2 | 9 |
| U1 snRNP | U1 small nuclear ribonucleoprotein | 2 |
| UACR | urine albumin-to-creatinine ratio | 59 |
| UCP | uncoupling protein | 1 |
| UCP1 | uncoupling protein 1 | 30 |
| UDSMR | Uniform Data System for Medical Rehabilitation | 3 |
| UGT | UDP-glucuronosyltransferase | 39 |
| UICC | Union for International Cancer Control | 21 |
| UIP | usual interstitial pneumonia | 141 |
| ULN | upper limit of normal | 170 |
| ULT | urate-lowering therapy | 39 |
| uPA | urokinase-type plasminogen activator | 6 |
| USPSTF | US Preventive Services Task Force | 16 |
| UTI | urinary tract infection | 321 |
| UVA | ultraviolet A | 52 |
| UVB | ultraviolet B | 73 |
| VACB | vacuum-assisted core biopsy | 1 |
| VAS | visual analog scale | 35 |
| vCJD | variant Creutzfeldt-Jakob disease | 17 |
| VDRL | Venereal Disease Research Laboratory | 50 |
| VEE | Venezuelan equine encephalitis | 12 |
| VEGF | vascular endothelial growth factor | 369 |
| VEGF-A | vascular endothelial growth factor A | 36 |
| VEGFR | vascular endothelial growth factor receptor | 83 |
| VEGFR-1 | VEGF receptor 1 | 9 |
| VEGFR-2 | VEGF receptor 2 | 0 |
| VHL | von Hippel-Lindau | 168 |
| VIC | valvular interstitial cell | 4 |
| VLCFA | very-long-chain fatty acid | 76 |
| VLDL | very-low-density lipoprotein | 67 |
| VLP | virus-like particle | 18 |
| VMAT2 | vesicular monoamine transporter 2 | 58 |
| VRE | vancomycin-resistant enterococci | 94 |
| VTE | venous thromboembolism | 273 |
| VWD | von Willebrand disease | 42 |
| vWF | von Willebrand factor | 137 |
| VWF | von Willebrand factor | 340 |
| VZV | varicella-zoster virus | 271 |
| WAI | Walking Ability Index | 21 |
| WEE | western equine encephalitis | 14 |
| WHI | Women's Health Initiative | 16 |
| WHO | World Health Organization | 2788 |
| WPW | Wolff-Parkinson-White | 51 |
| WSES | World Society of Emergency Surgery | 4 |
| XDR-TB | extensively drug-resistant tuberculosis | 19 |
| XLD | xylose lysine deoxycholate | 5 |
| XLH | X-linked hypophosphatemia | 9 |
| XOR | xanthine oxidoreductase | 15 |
| Y-BOCS | Yale-Brown Obsessive Compulsive Scale | 11 |
| Y-BOCS-II | Yale-Brown Obsessive Compulsive Scale Second Edition | 3 |
| Y-BOCS-SR | Yale-Brown Obsessive Compulsive Scale Self-Report | 3 |
| YOPS | Yersinia outer proteins | 10 |
| ypTNM | post-neoadjuvant pathological TNM | 8 |
| Z-POEM | peroral endoscopic myotomy for Zenker diverticulum | 2 |
| ZSD | Zellweger spectrum disorder | 27 |
| α-Gal A | alpha-galactosidase A | 8 |
該当する略語が見つかりませんでした。